直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 115039
タイトル別表記
Chimeric Anti-PDPN Antibody ChLpMab-2
著者
Kaneko, Mika K. Tohoku University
Yamada, Shinji Tohoku University
Nakamura, Takuro Tohoku University
Kunita, Akiko The University of Tokyo
Fukayama, Masashi The University of Tokyo
Fujii, Yuki Tohoku University
Ogasawara, Satoshi Tohoku University|Chiba University
Kato, Yukinari Tohoku University|Tohoku University|New Industry Creation Hatchery Center
キーワード
Antibody-dependent cellular cytotoxicity
chimeric antibody
human podoplanin
monoclonal antibody
資料タイプ
学術雑誌論文
抄録
Human podoplanin (hPDPN ), a platelet aggregation‐inducing transmembrane glycoprotein, is expressed in different types of tumors, and it binds to C‐type lectin‐like receptor 2 (CLEC ‐2). The overexpression of hPDPN is involved in invasion and metastasis. Anti‐hPDPN monoclonal antibodies (mAbs) such as NZ ‐1 have shown antitumor and antimetastatic activities by binding to the platelet aggregation‐stimulating (PLAG ) domain of hPDPN . Recently, we developed a novel mouse anti‐hPDPN mAb, LpMab‐2, using the cancer‐specific mAb (CasMab) technology. In this study we developed chLpMab‐2, a human–mouse chimeric anti‐hPDPN antibody, derived from LpMab‐2. chLpMab‐2 was produced using fucosyltransferase 8‐knockout (KO ) Chinese hamster ovary (CHO )‐S cell lines. By flow cytometry, chLpMab‐2 reacted with hPDPN ‐expressing cancer cell lines including glioblastomas, mesotheliomas, and lung cancers. However, it showed low reaction with normal cell lines such as lymphatic endothelial and renal epithelial cells. Moreover, chLpMab‐2 exhibited high antibody‐dependent cellular cytotoxicity (ADCC ) against PDPN ‐expressing cells, despite its low complement‐dependent cytotoxicity. Furthermore, treatment with chLpMab‐2 abolished tumor growth in xenograft models of CHO /hPDPN , indicating that chLpMab‐2 suppressed tumor development via ADCC . In conclusion, chLpMab‐2 could be useful as a novel antibody‐based therapy against hPDPN ‐expressing tumors.
掲載誌名
Cancer Medicine
ISSN
20457634
出版者
John Wiley & Sons
6
4
開始ページ
768
終了ページ
777
発行日
2017-03-23
権利情報
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
薬学系
医学系